Last reviewed · How we verify
Foraseq®
Foraseq is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD.
Foraseq is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD. Used for Maintenance treatment of asthma, Maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease).
At a glance
| Generic name | Foraseq® |
|---|---|
| Also known as | Formoterol/Budesonide |
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | ICS/LABA combination |
| Target | Glucocorticoid receptor; Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
The drug combines an inhaled corticosteroid (ICS) to reduce airway inflammation with a long-acting beta-2 agonist (LABA) to provide bronchodilation. This dual mechanism addresses both the inflammatory and obstructive components of chronic respiratory disease, improving airway function and reducing exacerbations.
Approved indications
- Maintenance treatment of asthma
- Maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
- A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma (PHASE3)
- A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foraseq® CI brief — competitive landscape report
- Foraseq® updates RSS · CI watch RSS
- Eurofarma Laboratorios S.A. portfolio CI